Scilex Holding Co [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	S-1/A	10-K	10-Q	10-Q	10-K	10-Q/A	10-Q
Operating activities
Net loss				-27.0		1.1

Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization				1.9
Amortization of debt issuance costs and debt discount				3.1
Loss on debt extinguishment, net				4.8
Stock-based compensation				2.8
Loss (gain) on derivative liability				-4.8	0.5
Changes in operating assets and liabilities:
Accounts receivables, net				-1.6
Inventory				1.4
Other long-term assets				0.1
Accounts payable				-3.5		-3.8
Accrued Payroll				0.9
Accrued expenses				-1.0	-3.3	-3.2
Other liabilities				-0.1
Related party payable				8.8
Net cash used for operating activities				-47.7	-25.6	-25.2

Investing activities
Net cash used for investing activities				-2.1	-1.0	-139.4

Financing activities
Proceeds from other loans				9.9
Proceeds from stock options and warrants exercised				0.1
Proceeds from related party payable				65.2		47.9
Proceeds from related party note payable				62.5
Net cash proceeds from financing activities				55.8	29.7	168.3

Supplemental disclosure:
Supplemental disclosure of non-cash financing activity
Related party debt converted to equity
Non-cash Consideration in Semnur Acquisition
Other Loan Forgiveness
Acquisition of right-of-use asset
Live Action right-of-use asset in Palo Alto
Non-cash distribution to Sorrento
Issuance of shares to Yorkville
Scilex Pharma Notes principal increase
Scilex Pharma Notes principal increase
Accrual for transaction costs related to the Business Combination
Transaction costs obligation assumed by Sorrento
Deferred underwriting fee payable
Offering costs included in accrued offering costs